Edesa Biotech is set to continue Phase II/III clinical study of its drug candidate, EB05, to treat patients hospitalised with Covid-19 on receiving an independent Data and Safety Monitoring Board’s (DSMB) recommendation.
Biopharma firm Edesa Biotech has received clearance from the US Food and Drug Administration (FDA) to initiate the Phase II part of Phase II / III clinical trial of its investigational drug EB05 to treat hospitalised patients with Covid-19.